TABLE 1.
Parameter | Characteristic | Data |
Age (y) | 64 ± 12 | |
Sex | Female | 26/51 (51%) |
Male | 25/51 (49%) | |
Indication for SSTR PET/CT | Staging | 15/51 (29.4%) |
Restaging | 36/51 (70.6%) | |
Ki-67 (%) | 4 ± 13 | |
Grade* | G1 | 23/48 (47.9%) |
G2 | 22/48 (45.8%) | |
G3 | 3/48 (6.3%) | |
Primary | Gastroenteropancreatic NET, in total | 41/51 (80.4%) |
Ileum/jejunum/mesenterial | 25/41 (61%) | |
Pancreas | 11/41 (26.8%) | |
Rectum | 3/41 (7.3%) | |
Colon | 2/41 (4.9%) | |
Non-gastroenteropancreatic NET, in total | 10/51 (19.6%) | |
Lung | 5/10 (50%) | |
Cancer of unknown primary | 5/10 (50%) | |
Prior therapies | Prior therapies, in total | 43/51 (84.3%) |
Surgery | 30/43 (69.8%) | |
Cold somatostatin analogs | 23/43 (53.5%) | |
PRRT | 15/43 (34.9%) | |
Chemotherapy | 10/43 (23.3%) | |
Locoregional procedures | 3/43 (7%) | |
Tyrosine kinase inhibitor | 1/43 (2.3%) |
Available in 48/51 (94.1%).
Qualitative data are numbers followed by percentages in parentheses; continuous data are mean ± SD.